Roger Ulrich received his Ph.D. in cellular and molecular biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He was a senior scientist with both The Upjohn Company and Pharmacia & Upjohn before moving to Abbott Laboratories as a director of drug safety research. He left Abbott to join Merck Research Laboratories – Rosetta Inpharmatics as a senior scientific director. Dr. Ulrich was a co-founder and chief development officer with Calistoga Pharmaceuticals, where he guided the development of CAL-101 (GS1101, idelalisib), an isoform-selective PI3K inhibitor and helped guide the acquisition of Calistoga by Gilead Sciences. As both a member of Acerta Pharma’s founding board of directors and as its chief scientific officer he helped facilitate a majority-share acquisition by AstraZeneca for the development of acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor. He holds several patents, has authored more than 120 publications, and is a fellow of the Academy of Toxicological Science and a senior advisor on the Frazier Life Sciences team.